Compare KALV & ACDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KALV | ACDC |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2014 | 2021 |
| Metric | KALV | ACDC |
|---|---|---|
| Price | $26.68 | $7.43 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | ★ $32.60 | $5.50 |
| AVG Volume (30 Days) | ★ 2.7M | 1.2M |
| Earning Date | 07-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $50,000,000.00 | ★ $1,941,800,000.00 |
| Revenue This Year | $185.42 | N/A |
| Revenue Next Year | $59.23 | $11.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $3.08 |
| 52 Week High | $26.76 | $10.70 |
| Indicator | KALV | ACDC |
|---|---|---|
| Relative Strength Index (RSI) | 75.31 | 64.79 |
| Support Level | $14.43 | $3.48 |
| Resistance Level | N/A | $8.43 |
| Average True Range (ATR) | 0.97 | 0.35 |
| MACD | 0.53 | 0.12 |
| Stochastic Oscillator | 99.01 | 83.29 |
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
ProFrac Holding Corp is a technology-focused, vertically integrated energy services company providing hydraulic fracturing, proppant production, completion services, and related products, including distributed power generation, to upstream oil and natural gas companies in the United States. The Company operates through four segments: Stimulation Services, Proppant Production, Manufacturing, and Flotek. The Stimulation Services segment, which generates maximum revenue, provides hydraulic fracturing services using mobile units and auxiliary equipment. The Proppant Production segment supplies proppant, the Manufacturing segment sells engineered products such as pumps, valves, and piping, and Flotek is a chemistry and data technology company serving the E&P industry.